Combination therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of immunotherapy (iparomlimab and tuvonralimab) plus a targeted therapy (bevacizumab) with focused radiation to the tumor for people with liver cancer that cannot be removed surgically. The goal is to see if this combination can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a diagnosis of liver cancer (hepatocellular carcinoma) that cannot be removed with surgery and is not suitable for other standard procedures like ablation or TACE.
- Your cancer is either only in the liver (but cannot be removed) or has spread to just a few spots outside the liver (5 or fewer) — but not in the brain.
- You have not had whole-body therapy before, or you have tried one line and it stopped working or caused side effects, and you have been off it for more than 3 weeks.
- You are in good enough health to perform daily activities (ECOG 0 or 1), and your liver, kidney, and blood tests meet the study's levels.
- You do not have significant bleeding risk, such as recent stomach bleeding or a bleeding disorder, and you must be willing to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.